| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -133,725 | -94,879 |
| Stock-based compensation expense | 16,260 | 11,028 |
| Depreciation and amortization expense | 9,142 | 6,576 |
| Loss on securities purchase agreement put/call | -4,029 | - |
| Net amortization and accretion on marketable securities | 3,899 | 2,890 |
| Loss on property and equipment disposals, net | -3,510 | -3,759 |
| Non-cash lease income | 2,511 | 1,516 |
| Change in fair value of contingent consideration payable | 1,706 | 2,075 |
| Impairment of long-lived assets | 1,443 | 1,443 |
| Change in fair value of success payment liabilities | 221 | -240 |
| Loss (gain) on marketable equity security | -29 | -28 |
| Impairment of other investments | 0 | 0 |
| Prepaid expenses, other current assets and other assets | -5,216 | -4,796 |
| Accounts payable | -2,664 | -1,885 |
| Accrued liabilities and other current liabilities | -12,546 | -13,118 |
| Other non-current liabilities | -572 | -223 |
| Net cash used in operating activities | -117,773 | -89,196 |
| Purchases of property and equipment | 476 | 414 |
| Sales of property and equipment | 263 | - |
| Purchases of marketable securities | 236,099 | 165,112 |
| Maturities of marketable securities | 321,774 | 247,639 |
| Net cash provided by investing activities | 85,462 | 82,113 |
| Proceeds from securities purchase agreement equity issuance | 50,000 | - |
| Proceeds from exercise of stock options | 0 | 0 |
| Proceeds from employee stock purchase plan | 184 | 184 |
| Taxes paid related to net share settlement of equity awards | 0 | 0 |
| Net cash provided by financing activities | 50,184 | 184 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 17,873 | -6,899 |
| Cash and cash equivalents at beginning of period | 107,287 | - |
| Cash and cash equivalents at end of period | 125,160 | - |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)